Skip to content
DataLookout
Menu

INOVATENCT07134153

Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)

At risk: Primary completion moved 5 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 18 words Show 5 more changesShow less
    • Primary endpoints: details revised at 1 of 12 entries
    • Primary completion pushed from Aug 30, 2026 to Jan 30, 2027
    • Study completion pushed from Feb 28, 2027 to Jun 28, 2027
    • Start date: Apr 18, 2025 to May 12, 2025
    • Study description expanded, about 36 words
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Phase I Stage Cohort A: Maximum Tolerated Dose (MTD)
Timeframe: Up to 21 days after the first dose
Phase I Stage Cohort B: Maximum serum concentration (Cmax)
Timeframe: Up to 21 days after the first dose
Phase I Stage Cohort B:Time to maximum serum concentration (Tmax)
Timeframe: Up to 21 days after the first dose
Phase I Stage Cohort B:Half-life (T1/2)
Timeframe: Up to 21 days after the first dose
Phase II Stage Cohorts A: LM-OS
Timeframe: 18 months
Phase II Stage Cohorts B: LM-OS
Timeframe: 18 months
Phase II Stage Cohorts C: LM-ORR
Timeframe: 18 months
Phase II Stage Cohorts D: LM-ORR
Timeframe: 18 months
Phase II Stage Cohorts E: LM-OS
Timeframe: 18 months
Phase II Stage Cohorts F: LM-OS
Timeframe: 18 months
Phase II Stage Cohorts G: LM-ORR
Timeframe: 18 months
Phase II Stage Cohorts H: LM-ORR
Timeframe: 18 months

Arms and interventions

Phase I/Arm A(Intrathecal Dose-Escalation Phase)Experimental

Population : T-DXd-naïve subjects with leptomeningeal metastases (LM), with or without concurrent brain metastases (BM). Cycle 1 : Intrathecal (IT) T-DXd monotherapy to assess cerebrospinal fluid (CSF) and systemic pharmacokinetics (PK). Cycles 2+ : IT T-DXd combined with intravenous (IV) T-DXd in a dose-escalation design to determine the maximum tolerated dose (MTD) . DLT Evaluation : The first two cycles serve as the dose-limiting toxicity (DLT) observation window . Endpoint : The recommended Phase 2 dose (RP2D) will be determined by investigator assessment

Phase I/Arm B(Systemic-to-Intrathecal Transition Phase)Experimental

Population : T-DXd-naïve subjects with LM ± BM. Cycle 1 : IV T-DXd monotherapy to characterize CSF and systemic PK profiles. Cycles 2+ : IT administration of the RP2D of T-DXd combined with IV therapy

Phase II/Arm AExperimental

HER2-positive advanced breast cancer with progressive leptomeningeal and/or brain metastases after prior T-DXd therapy

Phase II/Arm BExperimental

HER2-low (IHC 1+ or 2+/ISH-) advanced breast cancer with progressive leptomeningeal and/or brain metastases after prior T-DXd therapy

Phase II/Arm CExperimental

HER2-positive advanced breast cancer with progressive brain metastases (without leptomeningeal involvement) after prior T-DXd therapy

Phase II/Arm DExperimental

HER2-low advanced breast cancer with progressive brain metastases (without leptomeningeal involvement) after prior T-DXd therapy

Phase II/Arm EExperimental

T-DXd-naïve HER2-positive advanced breast cancer with progressive leptomeningeal and/or brain metastases

Phase II/Arm FExperimental

T-DXd-naïve HER2-low advanced breast cancer with progressive leptomeningeal and/or brain metastases

Phase II/Arm GExperimental

T-DXd-naïve HER2-positive advanced breast cancer with progressive brain metastases (without leptomeningeal involvement)

Phase II/Arm HExperimental

T-DXd-naïve HER2-low advanced breast cancer with progressive brain metastases (without leptomeningeal involvement)

Drugs: T-DXd

Sites

2 sites in 1 country